119,200 doses of the AstraZeneca COVID-19 vaccine shared by the United Kingdom are landing in Zambia and 51,840 in the Democratic Republic of the Congo (DRC) on 13 August. 119,040 doses are due to arrive in Malawi on 14 August, 140,160 doses in Senegal on 15 August, 299,680 doses in Egypt on 16 August, and 299,520 doses are scheduled to touch down in Uganda on 18 August. The UK has pledged to share 80 million doses of COVID-19 vaccines with COVAX, as part of a broader pledge to share 100 million doses with the rest of the world. The UK Government has already committed £548 million in funding to the Gavi COVAX Advance Market Commitment.
Foreign Secretary Dominic Raab: “Three million doses of UK-donated vaccines are now arriving in 11 countries across Africa, including Ethiopia, Kenya and Uganda, to help the fight against COVID-19. This is the first batch of 80 million being donated via COVAX – because we know no one is safe until everyone is safe.”
Dr Seth Berkley, CEO, Gavi, the Vaccine Alliance: “The Government of the United Kingdom has been one of global vaccination’s strongest advocates and an early supporter of COVAX. Dose donations play an important part in COVAX’s mission, especially now as we wait for deliveries to ramp up aggressively in the weeks to come. These deliveries will have a direct impact on protecting some of the most vulnerable people in the world.”
Geneva, 13 August 2021 – The first AstraZeneca doses donated to COVAX by the United Kingdom (UK) will soon arrive in Angola, Egypt, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Senegal and Uganda, with Zambia and DRC set to be the first to receive these UK-donated vaccines. 119,200 doses will be touching down in Lusaka and 51,840 doses in Kinshasa on 13 August. 119,040 doses are due to arrive in Malawi on 14 August, 140,160 doses in Senegal on 15 August, 299,680 doses in Egypt on 16 August, and 299,520 doses are scheduled to touch down in Uganda on 18 August. The remaining doses will arrive in their recipient countries in the near future.
This shipment of UK-donated doses is part of a broader pledge to share 100 million jabs with the rest of the world, of which 80% will be through COVAX. The UK has already donated approximately 5 million vaccine doses to COVAX and the total number of doses being sent to African countries in this delivery is approximately 3 million. As part of their vaccine donation, UK is also covering the costs of syringes, safety boxes, air freight and other ancillary costs. This UK support will help COVAX deliver at a time when global supply is still under significant pressure, and these deliveries in Q3 of 2021 are particularly important in meeting urgent needs and protecting vulnerable populations as new variants spread.
It comes after £548 million in UK funding to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) to help COVAX procure doses for 92 lower-income economies. The UK Presidency of the G7 was also instrumental in highlighting the agenda on access to vaccines, and agreeing major dose-sharing commitments with its G7 partners at the Carbis Bay G7 Summit.
Foreign Secretary Dominic Raab said: “Three million doses of UK-donated vaccines are now arriving in 11 countries across Africa, including Ethiopia, Kenya and Uganda, to help the fight against COVID-19. This is the first batch of 80 million being donated via COVAX – because we know no one is safe until everyone is safe.”
Health and Social Care Secretary Sajid Javid said: “The UK is proud to be a major supporter of COVAX and the crucial work it does in getting vaccines to countries that need them most. The five million doses donated to COVAX are part of our pledge to contribute 100 million vaccines within the next year to help accelerate global access, and it’s fantastic that from today the doses will be making a difference to millions of lives. I am hugely grateful to the University of Oxford and AstraZeneca for producing this vaccine at cost – after all, we are not safe from COVID-19 until the whole world is safe.”
CEO of Gavi, the Vaccine Alliance Dr Seth Berkley said: “The Government of the United Kingdom has been one of global vaccination’s strongest advocates and an early supporter of COVAX. Dose donations play an important part in COVAX’s mission, especially now as we wait for deliveries to ramp up aggressively in the weeks to come. These deliveries will have a direct impact on protecting some of the most vulnerable people in the world.”
These doses donated by the UK are produced by the AstraZeneca manufacturing network. Donating through COVAX helps to increase vaccine coverage, ensures that no dose goes to waste, and helps to bring an end to the acute phase of the pandemic. The design and operationalization of the COVAX dose sharing mechanism is being supported by a contribution of CAD 5 million from Canada.
More than 600 million doses have already been pledged to COVAX by a number of countries, helping us respond to short-term supply challenges. Thanks to the work of donor governments in overcoming legal and logistical hurdles, COVAX is operationalising increasing numbers of dose-sharing pledges, and we hope to see more deliveries of donated or transferred doses in the weeks and months to come.
Notes to editors
COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator , is co-led by CEPI, Gavi and WHO – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries.
CEPI’s role in COVAX
CEPI is leading on the COVAX vaccine research and development portfolio, investing in R&D across a variety of promising candidates, with the goal to support development of three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine. CEPI is also investing in the ‘next generation’ of vaccine candidates, which will give the world additional options to control COVID-19 in the future.
Gavi’s role in COVAX
Gavi is leading on procurement and delivery for COVAX, coordinating the design and implementation of the COVAX Facility and the COVAX AMC and working with Alliance partners UNICEF and WHO, along with governments, on country readiness and delivery. The COVAX Facility is the global pooled procurement mechanism for COVID-19 vaccines through which COVAX will ensure fair and equitable access to vaccines for all 190 participating economies, using an allocation framework formulated by WHO. The COVAX Facility will do this by pooling buying power from participating economies and providing volume guarantees across a range of promising vaccine candidates. The Gavi COVAX AMC is the financing mechanism that will support the participation of 92 low- and middle-income countries in the Facility, enabling access to donor-funded doses of safe and effective vaccines. UNICEF and the Pan-American Health Organisation (PAHO) will be acting as procurement coordinators for the COVAX Facility, helping deliver vaccines to all participants.
WHO’s role in COVAX
WHO has multiple roles within the COVAX: among other things it supports countries as they prepare to receive and administer vaccines and does so in partnership with UNICEF. It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. Its Strategic Advisory Group of Experts (SAGE) on Immunization develops evidence-based immunization policy recommendations. Its Emergency Use Listing (EUL)/prequalification programmes ensure harmonized review and authorization across member states. It provides global coordination and member state support on vaccine safety monitoring. It developed the target product profiles for COVID-19 vaccines and provides R&D technical coordination. Along with COVAX partners, it is developing a no-fault compensation scheme for indemnification and liability issues. COVAX is part of the Act accelerator which WHO launched with partners in 2020.
UNICEF’s role in COVAX
UNICEF is leveraging its experience as the largest single vaccine buyer in the world and working with manufacturers and partners on the procurement of COVID-19 vaccine doses, as well as freight, logistics and storage. UNICEF already procures more than 2 billion doses of vaccines annually for routine immunisation and outbreak response on behalf of nearly 100 countries. In collaboration with the PAHO Revolving Fund, UNICEF is leading efforts to procure and supply doses of COVID-19 vaccines for COVAX. In addition, UNICEF, Gavi and WHO are working with governments around the clock to ensure that countries are ready to receive the vaccines, with appropriate cold chain equipment in place and health workers trained to dispense them. UNICEF is also playing a lead role in efforts to foster trust in vaccines, delivering vaccine confidence communications and tracking and addressing misinformation around the world.
The Access to COVID-19 Tools ACT-Accelerator, is a new, ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March 2020 and launched by the WHO, European Commission, France and The Bill & Melinda Gates Foundation in April 2020.
The ACT-Accelerator is not a decision-making body or a new organisation, but works to speed up collaborative efforts among existing organisations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible through the accelerated development, equitable allocation, and scaled up delivery of tests, treatments and vaccines, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organisations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it.
The ACT-Accelerator has four areas of work: diagnostics, therapeutics, vaccines and the health system connector. Cross-cutting all of these is the workstream on Access & Allocation.
About Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 822 million children – and prevented more than 14 million deaths, helping to halve child mortality in 73 lower-income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook and Twitter.
The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.
+41 79 682 18 95
- 41 79 529 92 87
+41 79 711 55 54
+41 22 909 29 20
+41 79 913 94 41